^
    18d
    Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
    Minocycline augmentation significantly improved anhedonia in patients with melancholic MDD. Reducing pro-inflammatory cytokines (especially IL-1β) may play an important role in the potential mechanism for efficacy.
    Clinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL1B (Interleukin 1, beta)
    |
    minocycline
    19d
    EMPHASIS-2: Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (clinicaltrials.gov)
    P3, N=934, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    minocycline
    19d
    MDR-ENDPlus: A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis (clinicaltrials.gov)
    P3, N=294, Not yet recruiting, Seoul National University Hospital
    New P3 trial
    |
    CD4 (CD4 Molecule)
    |
    delpazolid (LCB01-0371) • rifampicin
    20d
    19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2029
    Trial completion date
    |
    Rituxan (rituximab) • dexamethasone • Ruxience (rituximab-pvvr) • Lumoxiti (moxetumomab pasudotox) • aspirin
    21d
    A Novel Magnetically Targeted Intramedullary (MagIC-TI) Xenograft Model for Precise Leukemia Modeling and Drug Resistance Evaluation in the Bone Marrow Niche. (PubMed, J Immunol Res)
    Magnetically labeled doxorubicin (DOX)-resistant HL60 cells (Mag-Re) were injected into the femurs of NSG (nonobese diabetic [NOD] Cg-PrkdcscidIL2rgtm1Wjl/SzJ) mice using a patented microinjection syringe under localized magnetic guidance...The MagIC-TI model discriminated drug responses, showing effective tumor burden reduction with homoharringtonine (HHT) and unequivocal DOX resistance, a distinction that was obscured in heterogeneous IV models...The MagIC-TI model enables BM-targeted, rapid, and efficient leukemic engraftment and allows discrimination of drug sensitivity and resistance. This model provides a robust and reproducible platform for modeling the leukemia BM niche and for preclinical evaluation of niche-directed therapies.
    Preclinical • Journal
    |
    PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    doxorubicin hydrochloride • Synribo (omacetaxine mepesuccinate)
    22d
    Linezolid alleviates D-galactose-induced anxiogenic or depressive behaviors and memory impairment. (PubMed, Sci Rep)
    Taken together, these findings suggest that Lnz might possess antioxidant and neuroprotective-like effects besides its antibiotic properties, which could modulate D-gal-induced behavioral changes, including anxiety- and depression-like responses and a potential tendency to improve memory-like performance. These observations are exploratory and deserve further investigation.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase)
    23d
    Ellagic Acid Attenuates Gentamicin Nephrotoxicity by Integrated Modulation of ER Stress-Associated Apoptosis-Autophagy Crosstalk and Attenuation of Nrf2/HO-1 Signaling. (PubMed, Biomedicines)
    The key novel findings include selective suppression of IL-6, modulation of the apoptosis-autophagy balance, and attenuation of Nrf2/HO-1 signaling without direct reactive oxygen species (ROS) scavenging, demonstrating a multi-target framework for EA's renoprotective effects. These findings suggest that ellagic acid mitigates renal injury in a context-dependent manner rather than confirming a direct causal mechanism.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • HMOX1 (Heme Oxygenase 1) • KIM1 (Kidney injury molecule 1) • ATF6 (Activating Transcription Factor 6) • IL1B (Interleukin 1, beta)
    23d
    Local Subcutaneous Gentamicin for Prevention of Surgical Site Infection After Elective Cesarean Section (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Western Galilee Hospital-Nahariya | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    23d
    Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Global Alliance for TB Drug Development
    New P2 trial
    24d
    PROBE-DFU trial: Pilot trial assessing antibiotic duration in diabetic foot ulcers that probe to bone (ACTRN12624000266561)
    P=N/A, N=80, Recruiting, Austin Health | N=120 --> 80
    Enrollment change
    25d
    Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis (clinicaltrials.gov)
    P2, N=309, Active, not recruiting, Global Alliance for TB Drug Development | Trial completion date: Jun 2026 --> Feb 2027
    Trial completion date
    25d
    Antibiotic Irrigation and Suction Ureteral Access Sheath in RIRS (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, Hitit University | Not yet recruiting --> Recruiting
    Enrollment open